Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Key Messages

This opinion article discusses evidence for the effectiveness of fluvoxamine when used to treat patients with COVID-19.

The good safety profile of fluvoxamine is well-established and the drug is well-tolerated by all age groups, although side effects are more frequent if fluvoxamine is given in higher doses.

Published evidence suggests fluvoxamine is a robust anti-inflammatory drug that also modulates the immune response. It reduces cytokine levels, lowers the risk of thrombosis by reducing hypercoagulability, and may also have a direct antiviral activity.

Croatian Medical Journal

Publication Date: February 1, 2021
Peer Reviewed: No
Publication Type: Review/Commentary/Letter
DOI: https://www.doi.org/10.3325/cmj.2021.62.95

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Robert Marčec, Robert Likić